189 related articles for article (PubMed ID: 37426135)
1. Effective omalizumab treatment influenced eosinophil function in severe allergic asthmatics.
Yan H; Sun L; Ni Y; Du J; Liu D; Wang P; Cao J; Xu G; Tao Y; Dai R; Tang W
J Thorac Dis; 2023 Jun; 15(6):3115-3125. PubMed ID: 37426135
[TBL] [Abstract][Full Text] [Related]
2. Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a
Li J; Wang C; Liu C; Kang J; Kong L; Huang Y; Liu S; Huang M; Wang L; Fogel R; Jaumont X; Yang J; Zhong N
World Allergy Organ J; 2020 Dec; 13(12):100469. PubMed ID: 34611470
[TBL] [Abstract][Full Text] [Related]
3. [Clinical efficacy of omalizumab for treatment of moderate or severe allergic asthma in children with serum immunoglobulin E levels >1 500 IU/mL: a prospective study].
Luo MX; Hua S; Wei W
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Sept 15; 25(9):959-965. PubMed ID: 37718403
[TBL] [Abstract][Full Text] [Related]
4. [A real world study of anti-IgE monoclonal antibody in the treatment of allergic united airway disease].
Sui HJ; Zhen Z; Wang QG; Cong TC; Huang JJ; Hu Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Feb; 57(2):273-280. PubMed ID: 36797588
[No Abstract] [Full Text] [Related]
5. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis.
Chong W; Li H; Wang J
Front Allergy; 2023; 4():1236798. PubMed ID: 37908372
[TBL] [Abstract][Full Text] [Related]
7. Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
Adv Med Sci; 2011; 56(2):318-22. PubMed ID: 21940268
[TBL] [Abstract][Full Text] [Related]
8. Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab.
Suzukawa M; Matsumoto H; Ohshima N; Tashimo H; Asari I; Tajiri T; Niimi A; Nagase H; Matsui H; Kobayashi N; Shoji S; Ohta K
Respir Med; 2018 Jan; 134():95-102. PubMed ID: 29413515
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
[TBL] [Abstract][Full Text] [Related]
10. Relevance of TH2 Markers in the Assessment and Therapeutic Management of Severe Allergic Asthma: A Real-Life Perspective.
Caminati M; Vianello A; Chieco Bianchi F; Festi G; Guarnieri G; Marchi MR; Micheletto C; Olivieri M; Tognella S; Guerriero M; Senna G;
J Investig Allergol Clin Immunol; 2020; 30(1):35-41. PubMed ID: 30676321
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
12. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
[TBL] [Abstract][Full Text] [Related]
13. Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study.
Solidoro P; Patrucco F; de Blasio F; Brussino L; Bellocchia M; Dassetto D; Pivetta E; Riccio A; Heffler E; Canonica W; Rolla G; Bucca C
Ther Adv Respir Dis; 2019; 13():1753466619841274. PubMed ID: 31002021
[TBL] [Abstract][Full Text] [Related]
14. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
Pacheco-Galván A; Hinojosa-Macías M; Hurtado-Barbudo B; González-Cervera J; Sueiro-Bendito A
Med Clin (Barc); 2009 Oct; 133(12):460-3. PubMed ID: 19775710
[TBL] [Abstract][Full Text] [Related]
16. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.
Busse WW; Humbert M; Haselkorn T; Ortiz B; Trzaskoma BL; Stephenson P; Garcia Conde L; Kianifard F; Holgate ST
Ann Allergy Asthma Immunol; 2020 Feb; 124(2):190-196. PubMed ID: 31760132
[TBL] [Abstract][Full Text] [Related]
17. A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens.
Johansson SGO; Lilja G; Hallberg J; Nopp A
Immun Inflamm Dis; 2018 Sep; 6(3):382-391. PubMed ID: 29737044
[TBL] [Abstract][Full Text] [Related]
18. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab.
Noga O; Hanf G; Kunkel G
Int Arch Allergy Immunol; 2003 May; 131(1):46-52. PubMed ID: 12759489
[TBL] [Abstract][Full Text] [Related]
19. Factors reducing omalizumab response in severe asthma.
Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Matucci A; Vultaggio A; Ricci A; Cresti A; Santus P; Perrella A; Paggiaro PL
Eur J Intern Med; 2018 Jun; 52():78-85. PubMed ID: 29395935
[TBL] [Abstract][Full Text] [Related]
20. The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry.
Hutyrová B; Bystroň J;
Postepy Dermatol Alergol; 2018 Oct; 35(5):510-515. PubMed ID: 30429711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
